Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
*End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June..
*End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June..
Food crops are capable of growing mRNS fragments that can interfere with the DNA of a targeted organ, species, entire race - called..